An SLE diagnosis triggers immediate questions about what a medical aid must cover, for how long, and at what cost. This article provides direct answers and a practical action plan.
Does My Medical Aid Have to Cover This?
Yes. SLE is a CDL condition. Your scheme must fund CDL-registered medications indefinitely from a ring-fenced chronic benefit. Acute flares requiring hospitalisation and lupus nephritis specialist management are covered under PMB. These obligations exist regardless of your plan tier or savings balance.
Register for the CDL Benefit Now
Contact your scheme's chronic benefits department with: - Rheumatologist or physician letter confirming SLE (ICD-10: M32) - Supporting investigations (anti-dsDNA, ANA, or clinical documentation meeting classification criteria) - CDL registration form
Once registered, your medications shift from the medical savings account to the CDL benefit. This is financially significant — SLE medication costs are lifelong, and protecting them from your MSA preserves savings for other health expenses.
Hydroxychloroquine: Why It Matters and What to Expect
Hydroxychloroquine (Plaquenil) is the cornerstone of SLE treatment — prescribed to virtually all patients regardless of disease severity. It reduces flares, limits organ damage, lowers cardiovascular risk, and improves survival data in clinical trials. Cost: approximately R400/month; it is on most CDL formularies.
One important monitoring requirement: after five years of hydroxychloroquine use, annual ophthalmology screening for hydroxychloroquine retinopathy (a rare but irreversible retinal toxicity) is recommended. Ask your scheme whether this annual screening is funded under the CDL benefit or your ophthalmology/day-to-day benefit.
Ongoing Monitoring: What Your Scheme Should Cover
SLE requires regular laboratory monitoring even during remission: - Full blood count (cytopenias — anaemia, low platelets — are common) - Urine protein:creatinine ratio (early nephritis detection — this is critical) - Complement C3 and C4, anti-dsDNA (disease activity markers) - Renal and liver function (immunosuppressant toxicity monitoring)
These tests are needed every 1–3 months depending on disease activity and treatment. They are a necessary component of CDL-registered SLE management and should be funded accordingly. If your scheme is processing monitoring tests through the day-to-day benefit (which depletes your MSA) rather than the CDL benefit, raise this in writing with chronic benefits.
Belimumab (Benlysta): How to Get It Funded
If your rheumatologist recommends belimumab for persistently active disease, an exceptional-needs application is required. The motivation should document: - Current SLEDAI-2K score (typically ≥8 for active disease) - Anti-dsDNA level and complement C3/C4 values - Prior treatment history: hydroxychloroquine + at least one immunosuppressant (azathioprine or mycophenolate) at adequate dose and duration - Steroid burden (daily prednisolone dose and duration — helps justify biologic escalation) - Reference to BLISS-52 and BLISS-76 trial data and EULAR/ACR guideline recommendation
Monthly cost of belimumab: approximately R14,000. Most schemes recognise the evidence base when documentation is complete.
Lupus Nephritis: Escalate Your CDL Record
If you develop nephritis (detected by urine protein:creatinine ratio ≥ 0.5, or biopsy-confirmed), inform your medical aid that nephritis has developed as a complication of your SLE. Update your CDL record with the nephrologist as a co-treating specialist. This broadens your PMB entitlements and ensures nephrology consultation costs are processed correctly.
Pregnancy and SLE: A Special Planning Consideration
SLE is most common in women of childbearing age. Pregnancy in SLE carries specific risks — flares may increase during pregnancy, and active SLE at conception increases risks of pre-eclampsia, foetal growth restriction, and premature delivery. Planning matters:
- Hydroxychloroquine is safe and should be continued through pregnancy.
- Mycophenolate mofetil is teratogenic — it must be stopped at least three months before conception and switched to azathioprine.
- Pregnancy with SLE should be managed by both a rheumatologist and a high-risk obstetrician (maternal-foetal medicine specialist). Confirm both are covered under your plan and that maternity PMB applies.
Practical Checklist
| Action | Priority |
|---|---|
| Register for CDL (ICD-10: M32) | Immediate |
| Confirm hydroxychloroquine is on CDL formulary | This week |
| Start baseline monitoring (FBC, renal, urine PCR, anti-dsDNA, C3/C4) | Per rheumatologist schedule |
| Confirm monitoring tests are CDL-funded, not MSA-funded | This week |
| Ask about hydroxychloroquine retinopathy screening (5-year protocol) | At next rheumatologist visit |
| Check gap cover status (rheumatologist + nephrologist shortfalls) | This week |
Managing Flares: Understanding Your Rights
During an SLE flare requiring hospitalisation (e.g., severe nephritis, neuropsychiatric manifestations, haematological crisis), your scheme must fund the admission under PMB. If a flare is managed in the outpatient setting — high-dose prednisolone, additional monitoring, extra specialist visits — these may exceed your CDL benefit allocation. Document all flare events with your rheumatologist and ensure your CDL record is updated after each significant flare. An updated clinical record supports future exceptional-needs applications and pre-authorisation requests.
If your disease activity is escalating and your rheumatologist believes a change in treatment is needed, ask them to submit a treatment plan to your scheme's case management team proactively — before any new treatment begins. Proactive authorisation avoids the retrospective dispute cycle.
Support Resources
Lupus SA: www.lupussa.org — patient community and information Arthritis Foundation SA: www.arthritis.org.za — rheumatic disease advocacy
Talk to Eldon
Get help understanding your plan options →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).